Covid-19 vaccine failure in a patient with multiple sclerosis on ocrelizumab

Sridhar Chilimuri; Nikhitha Mantri; Sudharsan Gongati; Maleeha Zahid; Haozhe Sun

doi:10.3390/vaccines9030219

Covid-19 vaccine failure in a patient with multiple sclerosis on ocrelizumab

Sridhar Chilimuri, Nikhitha Mantri, Sudharsan Gongati, Maleeha Zahid, Haozhe Sun

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Vaccines will play a key role in ending the COVID-19 pandemic. Vaccination against infections remains an important part of the management of patients with multiple sclerosis. However, there are limited data about the safety and efficacy of the currently available COVID-19 mRNA vaccines in patients with multiple sclerosis receiving concurrent immunosuppressive therapies. Patients on B cell depleting therapy such as ocrelizumab have an attenuated vaccine response. We report the first case of COVID-19 vaccine failure in a patient with relapsing-remitting multiple sclerosis on B cell depleting therapy, ocrelizumab. We offer suggestions to improve vaccine efficacy in these patients.

Original language	English
Article number	219
Pages (from-to)	1-3
Number of pages	3
Journal	Vaccines
Volume	9
Issue number	3
DOIs	https://doi.org/10.3390/vaccines9030219
State	Published - 2021

Keywords

B-Cell
COVID-19
Humoral immunity
Multiple sclerosis
Ocrelizumab
Vaccination

Access to Document

10.3390/vaccines9030219

Cite this

@article{eee56201ac984daf9ec93b75b7813b7d,

title = "Covid-19 vaccine failure in a patient with multiple sclerosis on ocrelizumab",

abstract = "Vaccines will play a key role in ending the COVID-19 pandemic. Vaccination against infections remains an important part of the management of patients with multiple sclerosis. However, there are limited data about the safety and efficacy of the currently available COVID-19 mRNA vaccines in patients with multiple sclerosis receiving concurrent immunosuppressive therapies. Patients on B cell depleting therapy such as ocrelizumab have an attenuated vaccine response. We report the first case of COVID-19 vaccine failure in a patient with relapsing-remitting multiple sclerosis on B cell depleting therapy, ocrelizumab. We offer suggestions to improve vaccine efficacy in these patients.",

keywords = "B-Cell, COVID-19, Humoral immunity, Multiple sclerosis, Ocrelizumab, Vaccination",

author = "Sridhar Chilimuri and Nikhitha Mantri and Sudharsan Gongati and Maleeha Zahid and Haozhe Sun",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

doi = "10.3390/vaccines9030219",

language = "English",

volume = "9",

pages = "1--3",

journal = "Vaccines",

issn = "2076-393X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "3",

}

TY - JOUR

T1 - Covid-19 vaccine failure in a patient with multiple sclerosis on ocrelizumab

AU - Chilimuri, Sridhar

AU - Mantri, Nikhitha

AU - Gongati, Sudharsan

AU - Zahid, Maleeha

AU - Sun, Haozhe

PY - 2021

Y1 - 2021

N2 - Vaccines will play a key role in ending the COVID-19 pandemic. Vaccination against infections remains an important part of the management of patients with multiple sclerosis. However, there are limited data about the safety and efficacy of the currently available COVID-19 mRNA vaccines in patients with multiple sclerosis receiving concurrent immunosuppressive therapies. Patients on B cell depleting therapy such as ocrelizumab have an attenuated vaccine response. We report the first case of COVID-19 vaccine failure in a patient with relapsing-remitting multiple sclerosis on B cell depleting therapy, ocrelizumab. We offer suggestions to improve vaccine efficacy in these patients.

AB - Vaccines will play a key role in ending the COVID-19 pandemic. Vaccination against infections remains an important part of the management of patients with multiple sclerosis. However, there are limited data about the safety and efficacy of the currently available COVID-19 mRNA vaccines in patients with multiple sclerosis receiving concurrent immunosuppressive therapies. Patients on B cell depleting therapy such as ocrelizumab have an attenuated vaccine response. We report the first case of COVID-19 vaccine failure in a patient with relapsing-remitting multiple sclerosis on B cell depleting therapy, ocrelizumab. We offer suggestions to improve vaccine efficacy in these patients.

KW - B-Cell

KW - COVID-19

KW - Humoral immunity

KW - Multiple sclerosis

KW - Ocrelizumab

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85102695010&partnerID=8YFLogxK

U2 - 10.3390/vaccines9030219

DO - 10.3390/vaccines9030219

M3 - Article

AN - SCOPUS:85102695010

SN - 2076-393X

VL - 9

SP - 1

EP - 3

JO - Vaccines

JF - Vaccines

IS - 3

M1 - 219

ER -

Covid-19 vaccine failure in a patient with multiple sclerosis on ocrelizumab

Abstract

Keywords

Access to Document

Fingerprint

Cite this